Steven Kelly

CIK: 0001339478

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ARTL

ARTELO BIOSCIENCES, INC.

Director

CARM

Carisma Therapeutics Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

ARTL
ARTELO BIOSCIENCES, INC.
Jul 17, 2026
Award(A)
Stock Option (right to buy)
Direct
136 shares-
ARTL
ARTELO BIOSCIENCES, INC.
Jan 30, 2026
Award(A)
Stock Options (right to buy)
Direct
292 shares-
CARM
Carisma Therapeutics Inc.
Jan 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
500K shares-
ARTL
ARTELO BIOSCIENCES, INC.
Dec 20, 2024
Award(A)
Stock Option (right to buy)
Direct
1.8K shares-

		Type	Shares	Price		Ownership
Jul 17, 2026	ARTL ARTELO BIOSCIENCES, INC.	Award(A) Stock Option (right to buy)	136	-	-	Direct
Jan 30, 2026	ARTL ARTELO BIOSCIENCES, INC.	Award(A) Stock Options (right to buy)	292	-	-	Direct
Jan 28, 2025	CARM Carisma Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	500,000	-	-	Direct
Dec 20, 2024	ARTL ARTELO BIOSCIENCES, INC.	Award(A) Stock Option (right to buy)	1,750	-	-	Direct

1-4 of 4 transactions

About Kelly Steven

Kelly Steven (SEC CIK 0001339478) files insider reports with the SEC as Director of ARTELO BIOSCIENCES, INC. (ARTL) and President and CEO of Carisma Therapeutics Inc. (CARM).

Signal8 holds 4 ownership filings by Kelly Steven, all Form 4s, filed between Dec 23, 2024 and Jul 21, 2026. Those filings report 4 transactions, from Dec 20, 2024 to Jul 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Kelly Steven's filings is in SOLANA BEACH, CA.

Recent filings by Kelly Steven

Jul 17, 2026: Grant or award of ARTL derivative securities (Form 4, code A).
Jan 30, 2026: Grant or award of ARTL derivative securities (Form 4, code A).
Jan 28, 2025: Grant or award of CARM derivative securities (Form 4, code A).
Dec 20, 2024: Grant or award of ARTL derivative securities (Form 4, code A).

Other insiders filing for ARTELO BIOSCIENCES, INC. (ARTL)

MATSUI CONNIE, Director
Blayney Douglas, Director
Reyes Gregory, Director
EMANUELE ROBERT MARTIN, Director
FAVORITO TAMARA A, Director
Spring Mark Edward, Chief Financial Officer

How to read Form 4 transaction codes